title: BCR-ABL1transcripts (MR4.5) at post-transplant 3 months as an early predictor for long-term outcomes in chronic myeloid leukemia.
abstract: OBJECTIVE
  The aim of this study was to identify the role ofBCR-ABL1transcript level as a predictor for post-transplant relapse and outcome in patients who underwent allogeneic stem cell transplantation (SCT) for chronic phase (CP) chronic myeloid leukemia (CML).
  
  
  METHODS
  Of 101 patients receiving allograft in CML CP, 85 had available quantitative reverse transcriptase polymerase chain reaction data at post-transplant 3 months. These patients were divided into two groups according to molecular response (MR4.5), defined as aBCR-ABL1transcript level ≤ 0.0032% on the international scale, at 3 months based on receiver operating characteristic curve analysis of relapse.
  
  
  RESULTS
  The 4-year overall survival and event-free survival (EFS) were 80.6% and 57.3%, respectively, and the cumulative incidence of relapse at 4 years was 29.6% after a median follow-up of 126.4 months. We performed multivariate analyses including potential variables to evaluate the early predictive role of MR4.5at 3 months and found that MR4.5at 3 months was associated with a higher EFS (p= 0.028) and showed a trend for a lower relapse rate (p= 0.089).
  
  
  CONCLUSIONS
  our results imply that frequent molecular monitoring and immune suppressive therapy modulation are required for patients without reduction ofBCR-ABL1transcripts to this level after SCT.
authors.affiliation: Catholic Leukemia Research Institute, The Catholic University of Korea, Seoul, Korea.|Department of Hematology, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.
authors.forename: Sung-Eun
authors.initials: SE
authors.lastname: Lee
authors.affiliation: Catholic Leukemia Research Institute, The Catholic University of Korea, Seoul, Korea.
authors.forename: Soo Young
authors.initials: SY
authors.lastname: Choi
authors.affiliation: Catholic Leukemia Research Institute, The Catholic University of Korea, Seoul, Korea.
authors.forename: Soo-Hyun
authors.initials: SH
authors.lastname: Kim
authors.affiliation: Catholic Leukemia Research Institute, The Catholic University of Korea, Seoul, Korea.
authors.forename: Hye-Young
authors.initials: HY
authors.lastname: Song
authors.affiliation: Catholic Leukemia Research Institute, The Catholic University of Korea, Seoul, Korea.
authors.forename: Hea-Lyun
authors.initials: HL
authors.lastname: Yoo
authors.affiliation: Catholic Leukemia Research Institute, The Catholic University of Korea, Seoul, Korea.
authors.forename: Mi-Young
authors.initials: MY
authors.lastname: Lee
authors.affiliation: Catholic Leukemia Research Institute, The Catholic University of Korea, Seoul, Korea.
authors.forename: Ki-Hoon
authors.initials: KH
authors.lastname: Kang
authors.affiliation: Catholic Leukemia Research Institute, The Catholic University of Korea, Seoul, Korea.
authors.forename: Hee-Jeong
authors.initials: HJ
authors.lastname: Hwang
authors.affiliation: Catholic Leukemia Research Institute, The Catholic University of Korea, Seoul, Korea.
authors.forename: Eun-Jung
authors.initials: EJ
authors.lastname: Jang
authors.affiliation: Catholic Leukemia Research Institute, The Catholic University of Korea, Seoul, Korea.|Department of Hematology, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.
authors.forename: Dong-Wook
authors.initials: DW
authors.lastname: Kim
mesh_terms: D000293:Adolescent; D000328:Adult; D019540:Area Under Curve; D014408:Biomarkers, Tumor / Q000235:genetics*; D018572:Disease-Free Survival; D004359:Drug Therapy, Combination; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D006086:Graft vs Host Disease / Q000209:etiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D053208:Kaplan-Meier Estimate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000235:genetics* / Q000378:metabolism / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011237:Predictive Value of Tests; D016016:Proportional Hazards Models; D012372:ROC Curve; D012008:Recurrence; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012307:Risk Factors; D033581:Stem Cell Transplantation / Q000009:adverse effects / Q000401:mortality; D013997:Time Factors; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: C581634:BCR-ABL1 fusion protein, human; D014408:Biomarkers, Tumor; D007166:Immunosuppressive Agents; D016044:Fusion Proteins, bcr-abl
keywords: Allogeneic stem cell transplantation; Leukemia, myelogenous, chronic, BCR-ABL positive; Post-transplant relapse